Patrizia Paterlini-Brechot,
Professor of Oncology/Molecular Biology,
University Paris Descartes
Patrizia Paterlini-Brechot, MD, PhD, is Oncologist, Hematologist and Molecular Biologist. She is a Professor of Oncology/Molecular Biology at Paris Descartes University- Necker Hospital, with a triple task of research leader, academic teacher and hospital practitioner. Prof. Paterlini-Brechot developed and patented with her team the method ISET (Isolation by SizE of Tumor/Trophoblastic cells) allowing the sensitive isolation from blood of intact circulating tumor and fetal cells without loss and without the use of antibodies, now recognized as a breakthrough in the fields of predictive oncology and non-invasive prenatal diagnosis. ISET has been proven to allow early detection of tumor invasion as a way to diagnose invasive cancers before imaging. The same ISET approach, followed by single cell molecular analyses, has been proven to provide non-invasive prenatal diagnosis of recessive disorders like cystic fibrosis and spinal muscular atrophy and is potentially valid for all types of genetic disorders.
ISET: A New Approach for the Follow-Up and Early Diagnosis of Invasive Cancers
Wednesday, 24 October 2018 at 15:30
Add to Calendar ▼2018-10-24 15:30:002018-10-24 16:30:00Europe/LondonISET: A New Approach for the Follow-Up and Early Diagnosis of Invasive CancersExosomes and Liquid Biopsies Europe 2018 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com
Circulating Tumor Cells (CTC) and Circulating Tumor Microemboli (CTM) are Circulating Rare Cells which herald tumor invasion and are expected to provide an opportunity to improve the management of cancer patients and help to detect the most aggressive invasive cancers before other diagnostic approaches like imaging. An important issue in the CTC field is how to obtain highly sensitive and unbiased collection of these fragile and heterogeneous cells for their diagnosis and molecular study when they are extremely rare, particularly at the beginning of the invasion process. We report on the ISET® (Isolation by SizE of Tumor/Trophoblastic Cells) open system for marker-independent isolation of tumor cells from blood. ISET® allows to reliably diagnose and count CTC with unparalleled sensitivity and specificity. Independent published data from different research teams have demonstrated the superior clinical sensitivity and specificity of ISET®. They have also demonstrated the prognostic relevance of CTC detection by ISET® in patients with melanomas, as well as lung, colorectal, liver, pancreatic, head and neck, and ovarian cancers. Furthermore, the utility of theranostic characterization of CTC by ISET® has been demonstrated for non-small-cell lung cancers, castration-resistant prostate cancers, colorectal cancers, hepatocellular carcinomas and melanomas.
Add to Calendar ▼2018-10-24 00:00:002018-10-26 00:00:00Europe/LondonExosomes and Liquid Biopsies Europe 2018Exosomes and Liquid Biopsies Europe 2018 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com
Add to Calendar ▼2018-10-24 15:30:002018-10-24 16:30:00Europe/LondonISET: A New Approach for the Follow-Up and Early Diagnosis of Invasive CancersExosomes and Liquid Biopsies Europe 2018 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com
